While Japan has now granted its first emergency approval to Shionogi’s COVID-19 pill Xocova (ensitrelvir), the drug failed to win a unanimous vote by advisory panels, with skepticism lingering over its actual efficacy. To prep for the next emergency, which…
HOME > COMMENTARY
COMMENTARY
- COMMENTARY／Generic Makers Increase Investment, but Will Consumption Really Increase as Gov't Hopes？
February 4, 2008
- COMMENTARY／Full-Scale M&As Imminent among Dispensing Pharmacy Chains
January 28, 2008
- OPINION／The East versus West Dilemma
January 28, 2008
- COMMENTARY／Full-Scale M&As Imminent among Dispensing Pharmacy Chains
January 28, 2008
- No More Need for MRs？ -A Hell beyond the 2010 Crisis？-
January 14, 2008
- COMMENTARY／Year 2007 in Retrospect
December 24, 2007
- COMMENTARY／Appreciation Mixed with Concern: Proposed NHI Pricing Reform
December 17, 2007
- COMMENTARY／Fight over Medical Fee/NHI Price Revision Rates Begin
December 3, 2007
- COMMENTARY：Korosho Must Explain Its "Primary Doctor" System Proposal in Detail
October 1, 2007
- Gakkai, Specialty Certification and Industry by Mark Colby
September 10, 2007
- COMENTARY：Korosho Required to Cut \220 Bil. in Social Security Spending
September 3, 2007
- COMMENTARY／NHI Drug Pricing System Reform: Many Similarities in Proposals from JPMA, PhRMA, EFPIA
August 27, 2007
- COMMENTARY／Range of Drugs Re-priced due to Expansion of Market May Be Expanded
July 23, 2007
- COMMENTARY／Market for Osteoporosis Drugs Booms
July 9, 2007
- COMMENTARY／Pressure Mounting on Long-Listed Original Drugs
July 9, 2007
- COMMENTARY：Generic Firms Need Stronger Business Platform to Ensure Nationwide Stable Supply
June 25, 2007
- COMMENTARY／Provisional Deliveries without Agreement on Prices
June 11, 2007
- COMMENTARY／Show Road Map to the Goal - 30% Share for Generics
June 4, 2007
- COMMENTARY／Korosho to Consider Introduction of CU System
May 28, 2007
- Explosion of Shin-Etsu Chemical's Cellulose Production PlantGood Opportunity to Reconsider Raw Material Procurement System
April 30, 2007
ページ
As the year 2022 draws to a close, what are managers thinking at the world’s leading pharmaceutical companies and medical device companies? We surveyed 86 managers at these companies to find out what’s on their minds.For many managers, a common…
A Japanese reimbursement policy panel on November 16 saw a continued scuffle between members representing healthcare providers and payers over…
Deloitte Tohmatsu Consulting proposed three drug pricing schemes designed to trigger the consolidation of generic makers on October 27, offering…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…